Selegilina [Inn-Spanish]

Selegilina [Inn-Spanish] Brand names, Selegilina [Inn-Spanish] Analogs

Selegilina [Inn-Spanish] Brand Names Mixture

No information avaliable

Selegilina [Inn-Spanish] Chemical_Formula

C₁₃H₁₇N

Selegilina [Inn-Spanish] RX_link

http://www.rxlist.com/cgi/generic/seleg.htm

Selegilina [Inn-Spanish] fda sheet

Selegilina_[Inn-Spanish] FDA

Selegilina [Inn-Spanish] msds (material safety sheet)

Selegilina_[Inn-Spanish] MSDS

Selegilina [Inn-Spanish] Synthesis Reference

Torok Z et al., Acta Pharm Hung. 1992 Sep;62(5):201-11

Selegilina [Inn-Spanish] Molecular Weight

187.281 g/mol

Selegilina [Inn-Spanish] Melting Point

141-142 ^oC

Selegilina [Inn-Spanish] H₂O Solubility

No information avaliable

Selegilina [Inn-Spanish] State

Solid

Selegilina [Inn-Spanish] LogP

2.884

Selegilina [Inn-Spanish] Dosage Forms

Tablet

Selegilina [Inn-Spanish] Indication

For the adjunct treatment for Parkinson's disease.

Selegilina [Inn-Spanish] Pharmacology

Dopamine is an essential chemical that occurs in many parts of the body. It is the premature degradation of dopamine that results in the symptoms of Parkinson's disease. Monoamine oxidase (MAO) is an enzyme which accelerates the breakdown of dopamine. Selegiline can prolong the effects of dopamine in the brain by preventing its breakdown through seletively blocking MAO. It also may prevent the removal of dopamine between nerve endings and enhance release of dopamine from nerve cells.

Selegilina [Inn-Spanish] Absorption

Rapidly absorbed from the gastrointestinal tract.

Selegilina [Inn-Spanish] side effects and Toxicity

LD₅₀=63 mg/kg (rats, IV)

Selegilina [Inn-Spanish] Patient Information

Selegilina [Inn-Spanish] Organisms Affected

Humans and other mammals